Ikris Pharma Network Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.50 M
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 184.38%
- Profit Growth 116.54%
- Ebitda -59.67%
- Net Worth 27.73%
- Total Assets 57.01%
About Ikris Pharma Network
Ikris Pharma Network Private Limited (IPNPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 13 August 2014 and has a history of Ten years and five months. Its registered office is in Ghaziabad, Uttar Pradesh, India.
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.50 M, as per Ministry of Corporate Affairs (MCA) records.
Parveen Sikri and Bharat Sikri serve as directors at the Company.
Company Details
-
Location
Ghaziabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media
Corporate Identity Details
-
CIN/LLPIN
U74120UP2014PTC065470
-
Company No.
065470
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Aug 2014
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Ikris Pharma Network?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parveen Sikri
|
Director | 13-Aug-2014 | Current |
|
Bharat Sikri
|
Director | 13-Aug-2014 | Current |
Financial Performance of Ikris Pharma Network.
Ikris Pharma Network Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 184.38% increase. The company also saw a substantial improvement in profitability, with a 116.54% increase in profit. The company's net worth Soared by an impressive increase of 27.73%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ikris Pharma Network?
In 2020, Ikris Pharma Network had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Sattva Shilp LlpParveen Sikri is a mutual person
-
Dotcom Pharma Private Limited
Parveen Sikri and Bharat Sikri are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ikris Pharma Network?
Ikris Pharma Network has a workforce of 10 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ikris Pharma Network, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ikris Pharma Network's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.